A 32-year-old married woman from Bangalore presents to the infertility clinic with a 4-year history of primary infertility. She reports irregular menstrual cycles (every 45–90 days) since age 16, progressive weight gain, and difficulty conceiving despite regular unprotected intercourse. On examination: BMI 28 kg/m², mild hirsutism, no acanthosis nigricans. Pelvic ultrasound reveals bilateral ovarian cysts (5–8 mm) with increased stromal volume. Hormonal profile: LH 16 mIU/mL, FSH 5 mIU/mL, LH:FSH ratio 3.2:1, total testosterone 0.8 ng/mL (normal 0.2–0.6), prolactin 18 ng/mL (normal 5–25), TSH 2.1 mIU/L. Fasting glucose 92 mg/dL, fasting insulin 8 µIU/mL. What is the most appropriate management strategy to restore ovulation in this patient?

Explanation

## Clinical Diagnosis & Ovulatory Status **Key Point:** This patient has PCOD with anovulation (irregular cycles, elevated LH:FSH ratio, ultrasound findings) and primary infertility. She is lean-to-normal BMI (28 kg/m²), has normal insulin levels, and normal thyroid/prolactin — making her a **lean PCOD phenotype** with preserved insulin sensitivity. ## Mechanism of Anovulation in PCOD ```mermaid flowchart TD A[Elevated LH]:::outcome --> B[Premature follicle luteinization]:::outcome A --> C[Increased androgen production]:::outcome B --> D[Arrested follicle growth at 5-8 mm]:::outcome C --> D D --> E[Anovulation & Infertility]:::urgent F[Aromatase inhibitor: Letrozole]:::action --> G[Blocks estrogen feedback]:::outcome G --> H[Increased FSH secretion]:::outcome H --> I[Dominant follicle selection & growth]:::outcome I --> J[Ovulation & Pregnancy]:::outcome ``` ## Why Letrozole Over Clomiphene in This Patient | Feature | Clomiphene Citrate | Letrozole | Best Choice Here | |---------|-------------------|-----------|------------------| | Mechanism | Estrogen receptor antagonist | Aromatase inhibitor (↓ estrogen locally) | Letrozole | | Follicle quality | May be compromised (anti-estrogenic) | Better endometrial thickness & oocyte quality | Letrozole | | Pregnancy rate in PCOD | 40–50% per cycle | 50–60% per cycle | Letrozole | | Endometrial thickness | Often thin (< 7 mm) | Preserved | Letrozole | | Multiple pregnancy risk | 5–10% | 1–2% | Letrozole | | Ovarian hyperstimulation | Moderate risk | Lower risk | Letrozole | | Cumulative pregnancy rate (6 cycles) | 60–70% | 70–80% | Letrozole | **High-Yield:** Letrozole is now preferred over clomiphene in PCOD-related infertility because: 1. Higher ovulation and pregnancy rates 2. Better endometrial thickness (critical for implantation) 3. Improved oocyte quality 4. Lower multiple pregnancy risk 5. Fewer anti-estrogenic side effects ## Dosing & Monitoring Protocol **Clinical Pearl:** Standard letrozole protocol for PCOD ovulation induction: - **Dose:** 2.5 mg daily for 5 days (days 3–7 of cycle) - **Monitoring:** Transvaginal ultrasound from day 10 onwards - **Trigger:** hCG 10,000 IU IM when dominant follicle ≥ 18 mm - **Intercourse:** Timed intercourse 36–40 hours post-hCG - **Success:** Ovulation in 70–80% of cycles; pregnancy in 40–50% per cycle ## Why Other Options Are Suboptimal **Clomiphene (Option A):** While effective, letrozole is superior in PCOD due to better endometrial thickness and oocyte quality. Clomiphene is reasonable second-line if letrozole fails. **Gonadotropins (Option C):** Reserved for: - Clomiphene-resistant PCOD (no ovulation after 3–6 cycles) - Poor responders to letrozole - Requires intensive monitoring (daily ultrasound, daily injections) - Higher cost and OHSS risk - Not first-line in this patient with normal ovarian reserve **Ovarian Drilling (Option D):** Considered only after failure of medical ovulation induction (letrozole + gonadotropins). Laparoscopic ovarian drilling is reserved for gonadotropin-resistant PCOD; this patient has not yet tried letrozole. [cite:ASRM Guideline on PCOD & Infertility 2018; Cochrane Review on Letrozole vs Clomiphene 2020]